#USA #biotechnology #South San Francisco #ABS Bio #Cureline

ABS Bio Expands Its Reach with Cureline Acquisition

In a significant development for the biopharmaceutical industry, Analytical Biological Services, Inc., or ABS Bio, has completed the acquisition of Cureline, Inc. This deal broadens ABS Bio's access to critical biospecimens and enhances its service capabilities.

Founded in 2003 by Dr. Olga Potapova, Cureline has built a strong reputation over the last two decades, providing indispensable biospecimen procurement and histology services to numerous leading global biopharmaceutical companies. With its headquarters in South San Francisco, California, Cureline specializes in biospecimen procurement and analysis, histology, digital pathology, and other essential research services tailored to the needs of the biopharmaceutical community.

Ehab Alramahy, the CEO of ABS Bio, expressed his enthusiasm for this merger, stating, “Cureline has built an exceptional reputation in the biospecimens and research space, and we are excited to welcome their team to ABS. This acquisition meaningfully expands our capacity and expertise while enabling us to remain focused on what matters most for scientific breakthroughs: broader access to biospecimens, flawless execution, and outstanding customer experience from initial request to delivery.”

The integration of Cureline into ABS Bio is set to strengthen the company's position as a premier partner in specimen procurement, cell culture, and histology services. It will also enhance ABS Bio's ability to serve pharmaceutical and biotech customers, which are increasingly facing complex procurement needs and dynamic therapeutic programs.

Dr. Potapova also noted the alignment between the two companies, saying, “Cureline was built on scientific excellence, global collaboration, and commitment to partnerships in research and drug discovery. ABS and Cureline are highly complementary in customer focus, regional scope of biospecimen collections, and service capabilities. By joining forces, our teams can offer a broader platform supported by a wider biospecimen network, deeper services expertise, and expanded biorepository capabilities.”

ABS, established in 1990, has been at the forefront of accelerating research and discovery for major pharmaceutical and biotech companies. The organization's expertise lies in providing high-quality cells and tissues, along with custom biological products and services. This includes cell culture services, human biospecimens, and logistics, highlighting its commitment to delivering reliable procurement and processing solutions.

As a portfolio company of 3 Boomerang Capital, ABS Bio is underpinned by a robust investment strategy focused on the healthcare sector. The firm specializes in innovative investment partnerships, with a particular emphasis on biopharma outsourcing and tech-enabled services.

This acquisition not only underscores ABS Bio's commitment to expanding its service offering but also positions the company to meet the evolving needs of the biopharmaceutical landscape. By bringing Cureline into its operations, ABS Bio stands to benefit from enhanced service capabilities that can lead to faster and more efficient drug discovery processes.

In summary, the acquisition of Cureline by ABS Bio marks a strategic move that seeks to bolster the company's position in the biospecimen ecosystem, ensuring better accessibility and service execution for its clientele in an ever-competitive market. With both teams now collaborating, the expectation is to achieve significant advancements in biopharmaceutical research and development, which could pave the way for new therapeutic avenues and breakthroughs in future healthcare solutions.